Acute, Inc. v. ECI Pharmaceuticals, LLC

CourtDistrict Court, S.D. Florida
DecidedJune 18, 2025
Docket0:24-cv-61915
StatusUnknown

This text of Acute, Inc. v. ECI Pharmaceuticals, LLC (Acute, Inc. v. ECI Pharmaceuticals, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Acute, Inc. v. ECI Pharmaceuticals, LLC, (S.D. Fla. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

CASE NO. 24-CV-61915-RAR

ACUTE, INC.,

Appellant,

v.

ECI PHARMACEUTICALS, LLC,

Appellee. _____________________________________/

ORDER DISMISSING BANKRUPTCY APPEALS

THIS CAUSE comes before the Court on Appellee’s first Motion to Dismiss Appellant’s Pending Appeal (“First MTD”), [ECF No. 5], Motion for Leave to Amend Sale Order, [ECF No. 6], and Appellee’s second Motion to Dismiss Pending Appeal (“Second MTD”), [ECF No. 25]. Appellee ECI Pharmaceuticals, LLC (“ECI”) seeks to dismiss two appeals by Appellant Acute, Inc. (“Acute”) from a bankruptcy proceeding in the United States Bankruptcy Court for the Southern District of Florida, In re ECI Pharmaceuticals LLC, Case No. 24-14430-SMG (Bankr. S.D. Fla. 2024) (“In re ECI”). The Court having considered the Motions, applicable law, and the record in its entirety, it is hereby ORDERED AND ADJUDGED that Appellee’s First MTD, [ECF No. 5], is GRANTED, Appellee’s Motion for Leave to Amend Sale Order is DENIED AS MOOT, [ECF No. 6], and Appellee’s Second MTD, [ECF No. 25], is GRANTED. BACKGROUND I. The Bankruptcy On May 3, 2024, ECI and its affiliate BioRamo, LLC (“BioRamo”) (collectively, “Debtors”) each filed for Chapter 11 Bankruptcy in the United States Bankruptcy Court for the Southern District of Florida (“Bankruptcy Court”). In re ECI (Bankr. S.D. Fla. May 3, 2024), ECF No. 1; In re BioRamo LLC, Case No. 24-14431-SMG (Bankr. S.D. Fla. May 3, 2024), ECF No. 1. The bankruptcy cases are being jointly administered under Case No. 24-14430-SMG (“Bankruptcy Case”). See In re ECI (Bankr. S.D. Fla. May 7, 2024), ECF No. 15.1 II. First Appeal A. Sale Order On August 16, 2024, Debtors filed an Expedited Motion to Authorize and Approve

(I) Proposed Private Sale of Substantially All of Debtors’ Assets, and (II) Other Related Relief (“Sale Motion”). In re ECI (Bankr. S.D. Fla. Aug. 16, 2024), ECF No. 172. The Sale Motion sought the Bankruptcy Court’s approval of an undated Asset Purchase Agreement (“APA”), see id. at 19–30, by which Debtors would sell substantially all their assets to Acute in a private sale pursuant to 11 U.S.C. § 363(b)(1), see id. ¶ 20. With no objections to the Sale Motion, the Bankruptcy Court entered an Order on August 30, 2024, authorizing Debtors to sell substantially all their assets to Acute pursuant to the terms set out in the APA (“Sale Order”). See generally In re ECI (Bankr. S.D. Fla. Aug. 30, 2024), ECF No. 193. Per the Sale Order, Debtors and Acute were “free to close under the APA at any time, subject to the express terms of the APA.” Id. ¶ 5. B. Order Denying Reconsideration

At some point after the Bankruptcy Court entered the Sale Order, a dispute arose between Debtors and Acute regarding the parties’ closing obligations under the APA. On September 13, 2024, Acute filed a Motion for Reconsideration of the Sale Order (“Motion for Reconsideration”) pursuant to Bankruptcy Rules 9023 and 9024. See In re ECI (Bankr. S.D. Fla. Sept. 13, 2024), ECF No. 199. According to Acute, separate from the APA, Acute entered into a contract with a

1 Although ECI and Bioramo’s bankruptcy cases are being jointly administered, Acute names ECI as the sole Appellee in both of the appeals before the Court. company called South Florida Business Plaza (“SFBP”) to purchase the building and real estate where the Debtors operated their businesses (“Real Estate Contract”). Mot. for Recons. ¶ 4. Closing under the Real Estate Contract was to take place simultaneously with closing under the APA. See id. ¶ 26. However, Acute claimed that SFBP, “with the consent and knowledge of the Debtors, embarked on an aggressive course of conduct against Acute, with the ultimate goal of causing the failure of the sale of the real estate to Acute, which in turn would cause the failure of Acute to [ ] purchase the Debtors’ assets” under the APA. Id. ¶ 4.

First, in late August 2024, after Acute deposited escrow payments required under the APA and the Real Estate Contract into a trust account maintained by Acute’s counsel, counsel for Debtors and counsel for SFBP “began questioning and harassing” Acute’s counsel, “alleging that Acute was in breach of the APA and Real Estate Contract because [Acute’s counsel, acting as] escrow agent was not in possession of the deposit in ‘cleared funds[.]’” Id. ¶ 21. After some jostling between Acute, Debtors, and SFBP, Acute advised Debtors and SFBP that neither the Real Estate Contract nor the APA required the escrow deposits to be made in cleared funds, id. ¶¶ 21– 22, and subsequently, “this form of harassment ceased,” id. ¶ 23. Next, SFBP “decided to unilaterally impose a closing date on the Real Estate Contract for September 10, 2024.” See id. ¶ 24. In Acute’s view, this closing demand was “in violation of the

contractual obligations of the parties and in violation of the [Sale Order].” Id. ¶ 26. When Acute did not appear at the closing on September 10, 2024, SFBP declared that Acute was in default under the Real Estate Contract. See id. ¶ 26. Acute maintained that it was not required to close under either the Real Estate Contract or the APA because “[a]fter the entry execution of the APA and the Real Estate Contract,” Acute learned that Debtors were “not in the position to provide for an orderly transfer, assignment or use of” certain governmental licenses that were necessary for Acute to operate the business, the transfer of which was a condition precedent to closing under the APA. Id. ¶ 4. Therefore, Acute posited that the Bankruptcy Court needed to vacate and amend the Sale Order in order to clarify “when the closing on the APA and the Real Estate Contract needs to occur, in order to give the Debtors and Acute the time needed for the appropriate governmental agencies to allow Acute the ability to operate the businesses with the appropriate Licenses intact.” Id. Specifically, Acute requested that the “[Bankruptcy] Court modify the [Sale Order] to allow

sufficient time for appropriate procedures to be put in place to allow for the use, transfer and/or assignment of the Licenses so that Acute will be able to operate the businesses upon closing.” Id. ¶ 28. On September 25, 2025, the Bankruptcy Court held a hearing on the Motion for Reconsideration (“Sale Hearing”). See Sale Hearing Transcript, [ECF No. 13]. At the Sale Hearing, the Bankruptcy Court explained that it would deny the Motion for Reconsideration because it was an “inappropriate procedural vehicle” for Acute’s requested relief: the APA itself, not the Sale Order, specified the parties’ closing obligations; the Sale Order simply authorized Debtors to sell their assets to Acute. Id. at 5:10–6:4. The Bankruptcy Court further noted that the APA “is a binding contract and both sides have to perform.” Id. at 11:18. If Acute wanted the

Bankruptcy Court to determine the parties’ obligations under the APA, the proper procedural vehicle would be a motion to enforce, not to vacate, rehear, or amend the Sale Order: [I]t sounds like [Acute] agreed to certain terms and provisions regarding the license that maybe they weren’t prepared to fulfill timely, but this goes both ways, this is an utter mess on both sides, and you all need to decide, is there a deal to be had or is there not, and if there is, does somebody want me to enforce it or not. But the motion to reconsider is not the right vehicle. There is no basis to reconsider the entry of the [S]ale [O]rder, it was appropriate and there’s no grounds under Rule 59 or 60 to vacate or rehear that. Id. at 12:19–13:2. On September 27, 2024, the Bankruptcy Court issued a written Order memorializing its oral ruling denying the Motion for Reconsideration (“Order Denying Reconsideration”). See In re ECI (Bankr. S.D. Fla. Sept. 27, 2024), ECF No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nicolas Laurent v. Nancy N. Herkert
196 F. App'x 771 (Eleventh Circuit, 2006)
Englander v. Mills
95 F.3d 1028 (Eleventh Circuit, 1996)
Wright Ex Rel. Wright v. Hanna Steel Corp.
270 F.3d 1336 (Eleventh Circuit, 2001)
Westwood Community Two Ass'n v. Barbee
293 F.3d 1332 (Eleventh Circuit, 2002)
Tom L. Ashlock v. Conseco Services, LLC
381 F.3d 1251 (Eleventh Circuit, 2004)
Access Now, Inc. v. Southwest Airlines Co.
385 F.3d 1324 (Eleventh Circuit, 2004)
Big Top Koolers, Inc. v. Circus-Man Snacks, Inc.
528 F.3d 839 (Eleventh Circuit, 2008)
Singleton v. Wulff
428 U.S. 106 (Supreme Court, 1976)
Kontrick v. Ryan
540 U.S. 443 (Supreme Court, 2004)
In Re Global Industrial Technologies, Inc.
645 F.3d 201 (Third Circuit, 2011)
Gary Walker v. Charlie Jones, Warden
10 F.3d 1569 (Eleventh Circuit, 1994)
In Re Weston
18 F.3d 860 (Tenth Circuit, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Acute, Inc. v. ECI Pharmaceuticals, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/acute-inc-v-eci-pharmaceuticals-llc-flsd-2025.